Moderna Reports First Quarter 2026 Financial Results and Provides Business Updates

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports ...

Moderna reports mixed Q1 results as revenue beats estimates but litigation charge weighs on earnings

Moderna Inc (NASDAQ:MRNA, XETRA:0QF) reported first quarter 2026 revenue that came in well above Wall Street expectations, ...

Moderna Q1 preview: revenue rebound in focus as losses persist

Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to ...
Fierce Pharma

Sanofi touts tolerability of COVID shot Nuvaxovid in head-to-head trial vs. Moderna's mNexspike

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a ...

CureVac Patent Suit Targets Moderna’s Spikevax Covid-19 Shots

Moderna Inc. was hit with a new lawsuit alleging the vaccine maker’s Spikevax Covid-19 shots infringe 10 CureVac SE patents ...

Moderna Receives European Commission Marketing Authorization for mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's ...